MOTS-c vs SS-31: Mitochondrial Peptide Research Comparison
MOTS-c and SS-31 are often grouped together as mitochondrial peptides, but the mechanisms are different: mtDNA-encoded metabolic signalling versus cardiolipin-targeted inner-membrane stabilization.
MOTS-c and SS-31 both belong in mitochondrial research, but they do different jobs. MOTS-c is encoded in the mitochondrial 12S rRNA region and is studied for AMPK-linked metabolic flexibility, glucose handling, stress-response transcription, and diabetic-model bioenergetics.[1][2] SS-31, also called elamipretide, is a synthetic aromatic-cationic tetrapeptide studied for cardiolipin binding, inner-membrane structure, cristae architecture, and electron-transport-chain efficiency.[3][4]
Fast Comparison: MOTS-c vs SS-31
| Point of comparison | MOTS-c | SS-31 / Elamipretide |
|---|---|---|
| Core identity | 16-amino-acid mitochondrial-derived peptide encoded by a short open reading frame in mitochondrial 12S rRNA. | Synthetic tetrapeptide often described as D-Arg-2',6'-dimethylTyr-Lys-Phe-NH2. |
| Main research focus | Metabolic stress signalling, AMPK activation, glucose metabolism, and retrograde mitochondria-to-nucleus communication. | Cardiolipin binding, inner-membrane stabilization, mitochondrial ROS modulation, and respiratory-chain architecture. |
| Common model systems | Metabolic-flexibility, skeletal-muscle, beta-cell, diabetic-heart, and aging-stress models. | Mitochondrial dysfunction, cardiomyopathy, kidney injury, skeletal-muscle aging, and membrane/cristae models. |
| Evidence record | Strong preclinical and review literature; no completed late-stage human program establishing clinical use. | Broader translational record, including clinical-development literature around mitochondrial disease, but interpretation still depends on indication and endpoint. |
| Published on-site documentation | MOTS-c research review; no Remy batch record. | SS-31 research review; no Remy batch record. |
What Makes MOTS-c Different?
MOTS-c is unusual because it is encoded inside mitochondrial DNA rather than nuclear DNA. Lee et al. described it in Cell Metabolism as a 16-amino-acid peptide that promotes metabolic homeostasis and insulin sensitivity through a pathway involving folate-cycle modulation, AICAR accumulation, and AMPK activation.[1]
That origin matters. MOTS-c is usually discussed as a stress-responsive metabolic signal: a way mitochondria may communicate with the nucleus under energetic pressure.[2]
The clearest research endpoints are AMPK activity, glucose uptake, insulin-sensitivity markers, oxidative-stress response, beta-cell stress biology, and tissue-specific bioenergetic adaptation. "Mitochondrial support" is too vague for this compound.
What Makes SS-31 Different?
SS-31, also called elamipretide, belongs to the Szeto-Schiller family of mitochondria-targeted peptides. The most common mechanistic description is cardiolipin interaction at the inner mitochondrial membrane, with downstream effects on cristae structure, cytochrome c behavior, and electron-transport-chain efficiency.[3]
A separate biophysical literature describes SS-31 binding lipid bilayers and altering membrane properties. That helps explain why the peptide appears in mitochondrial dysfunction models, not just metabolic-signalling assays.[4]
SS-31 is usually the better match when the endpoint is mitochondrial membrane integrity, cardiolipin, oxidative phosphorylation, ROS generation, or cristae architecture. It is adjacent to MOTS-c, not a duplicate of it.
Evidence Strength and Limits
SS-31 has more human clinical-development literature because elamipretide has been evaluated in settings linked to mitochondrial disease and cardiac or skeletal-muscle endpoints — culminating in the FDA approval of Forzinity (elamipretide) for Barth syndrome and, in July 2026, first-patient dosing in the 4TAZPower Phase 4 confirmatory study. That does not validate every SS-31 claim, but it does put the compound beyond cell and rodent work alone.[3]
MOTS-c has a strong preclinical record, starting with the Cell Metabolism characterization and extending into cardiovascular, aging, metabolic-stress, and diabetes-model literature. Public literature still lacks a completed Phase 2 or Phase 3 program that establishes exogenous MOTS-c as a clinical intervention.[1][2]
Both molecules remain research-use-only catalog items. Both appear in the Dubai non-retatrutide research-vial catalog and COA map alongside the other research peptides. Treating them as one generic mitochondrial category hides the main difference: MOTS-c is about metabolic signalling; SS-31 is about mitochondrial membrane biology.
When to Use Each Compound in a Study
MOTS-c belongs in studies asking how a mitochondrial-derived peptide changes metabolic stress signalling. Relevant endpoints include AMPK activation, glucose uptake, gene-expression changes under stress, mitochondrial-to-nuclear signalling, beta-cell senescence markers, or diabetic-model bioenergetics.
SS-31 belongs in studies asking how a peptide changes mitochondrial membrane structure or respiratory efficiency. Relevant endpoints include cardiolipin organization, cristae morphology, oxidative phosphorylation, mitochondrial ROS, cytochrome c behavior, or tissue injury models where mitochondrial membrane integrity is central.
For product-format details, compare the MOTS-c research review and SS-31 research review. For broader background, continue to the standalone MOTS-c research profile, the SS-31 research profile, and the peptide stability guide.
Our Research Standards
This article uses peer-reviewed primary literature and reviews. Product references are limited to research-use format and verification. Read our editorial policy →
Mitochondrial Peptide FAQ
What is the main difference between MOTS-c and SS-31?
MOTS-c is a mitochondrial-derived peptide encoded in mitochondrial 12S rRNA and studied mainly for AMPK-linked metabolic signalling. SS-31 is a synthetic tetrapeptide studied for cardiolipin binding and inner-mitochondrial-membrane stabilization.
Which peptide has stronger translational evidence?
SS-31 has more human clinical-development literature: elamipretide was approved by the FDA as Forzinity for Barth syndrome in 2025, and a Phase 4 confirmatory study (4TAZPower) dosed its first patient in July 2026. MOTS-c has strong preclinical metabolic literature but no completed late-stage human program; in July 2026 the FDA compounding advisory committee voted 7-5 to recommend MOTS-c for the 503A compounding Bulks List, an advisory vote that is not an approval.
Can MOTS-c and SS-31 be treated as interchangeable mitochondrial peptides?
No. MOTS-c is mainly a metabolic-signalling peptide. SS-31 is mainly a cardiolipin- and membrane-targeted mitochondrial peptide. They are used for different questions.
What documentation does Remy Peptides publish for MOTS-c and SS-31?
Remy Peptides publishes research profiles for MOTS-c and SS-31. No Remy batch record exists for either compound; the published Janoshik COAs in the COA library cover retatrutide batches only.
Sources
- Lee C, Zeng J, Drew BG, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism. 2015;21(3):443-454. doi: 10.1016/j.cmet.2015.02.009 · PMID: 25738459 ↵
- The role of mitochondria-derived peptides in cardiovascular and metabolic research. PMC8396025 ↵
- Elamipretide: a review of its structure, mechanism of action, and mitochondrial research context. PMC11816484 ↵
- The mitochondria-targeted peptide SS-31 binds lipid bilayers and modulates membrane properties. PMC7247319 ↵
For catalog details, see MOTS-c 10mg and SS-31 10mg. For adjacent handling context, read the peptide stability guide.